Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01843478 · ClinicalTrials.gov registry record · NA

The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling

A NA study, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
97
Enrollment target

NCT01843478: Completed NA study, sponsored by Johns Hopkins University.

NCT01843478 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 97 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01843478, a NA study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
97 participants
Enrollment target

Study Summary

Cervical cancer is the second most common type of cancer among women worldwide. Women with human immunodeficiency virus (HIV) bear a disproportionate burden of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN), that result from persistent high-risk Human Papillomavirus (HPV) infection. HIV clinical practice guidelines recommend two Pap tests in the year following diagnosis, and if both are normal, yearly thereafter. Nationally, only 25% of women meet this recommendation. The mean annual Pap testing rate for federally funded HIV centers is only 55.7%. In 2009, quality improvement statistics from the Johns Hopkins Hospital Moore Clinic, a large urban HIV center, revealed an annual Pap testing rate of 59%. This occurred despite interventions to address adherence issues were implemented, including nurse case management, co-location of HIV and gynecology services, flexible scheduling, and continuity of care. Women keep their appointments for HIV primary care more often than for gynecology care in the Moore Clinic, so an intervention that takes place during a primary care visit could improve cervical cancer screening rates. The availability of HPV testing provides a unique opportunity to increase perceived susceptibility to and severity of cervical cancer among women with HIV, and to encourage follow-up Pap testing. HPV testing involves analyzing a sample of cervicovaginal cells for the presence of high-risk HPV strains. Detection of high-risk strains of the virus indicates a high risk for high grade CIN and cancer, while a negative HPV test predicts a less than 2% risk of developing CIN. HPV testing can be easily conducted by women themselves through self-collection in a primary care visit. Studies of women without HIV who do not have regular Pap testing have demonstrated that self-collected HPV testing and results counseling increases the overall screening rate, and women who test positive for HPV have a high rate of follow-up Pap testing. Sel

Primary Outcome

The outcome measure is the completion of Pap testing within 6 months of the baseline study visit.

Interventions

  • OTHER Usual Care
  • OTHER Self-Collected HPV Test

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2012-10
Est. Completion 2014-03
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT01843478 record still lists

NCT01843478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.

NCT01843478 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01843478 about?

NCT01843478 is a clinical study titled "The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling". Cervical cancer is the second most common type of cancer among women worldwide. Women with human immunodeficiency virus (HIV) bear a disproportionate burden of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN), that result from persistent high-risk Human Papillomavirus (HPV...

What is the current status of trial NCT01843478?

This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2012-10. Estimated completion is 2014-03.

What interventions are being tested in trial NCT01843478?

The interventions under investigation include: Usual Care (OTHER), Self-Collected HPV Test (OTHER).

Who is sponsoring clinical trial NCT01843478?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01843478's enrollment target sits among peer trials

97 923rd of 2000 higher than 1,076 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03948490 · 97 participants · NA

    Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

  • NCT04140487 · 97 participants · Phase 1

    Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  • NCT04196413 · 97 participants · Phase 1

    GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

  • NCT05223816 · 97 participants · Phase 2

    An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01843478, the US trial registry maintained by the National Library of Medicine. NCT01843478 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.